Brief: Actinium Completes Enrollment In The Pivotal Phase 3 Sierra Trial Of Iomab-B

Actinium Pharmaceuticals

15/09/2021 13:13

Sept 15 (Reuters) - Actinium Pharmaceuticals Inc  ATNM.A :
    * ACTINIUM COMPLETES ENROLLMENT IN THE PIVOTAL PHASE 3
SIERRA
TRIAL OF IOMAB-B
    * ACTINIUM PHARMACEUTICALS INC - DATA UPDATES EXPECTED IN
4Q:2021
WITH TOPLINE DATA IN MID-2022
    * ACTINIUM - LOWER RATES OF SERIOUS ADVERSE EVENTS INCLUDING
FEBRILE NEUTROPENIA, SEPSIS AND MUCOSITIS IN PATIENTS RECEIVING
IOMAB-B VERSUS CONTROL ARM

Source text for Eikon:  ID:nPn3wchkYa 
Further company coverage:  ATNM.A 

 ((Reuters.Briefs@thomsonreuters.com;))